A Phase 1 interventional study of Enlicitide Decanoate in Hypercholesterolaemia, sponsored by Merck Sharp & Dohme LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 24th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 in phase 1, and was the 21st registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 500 across the 27 interventional studies, 901 across the 2 observational. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Hypercholesterolemia by Merck & Co., Inc that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821944Phase 3Merck Sharp & Dohme LLCA Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) | 2027-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to compare the plasma pharmacokinetics (PK) of enlicitide decanoate following a single 20 mg dose in participants on a background of statin therapy with varying degrees of renal impairment (moderate, severe, end stage renal disease [ESRD]) to those of healthy mean matched control participants on a background of statin therapy. There is no formal hypothesis.
Panel C included participants with ESRD. No urine samples could be obtained on Panel C participants and hence no pharmacokinetic (PK) analysis could be performed for Panel C participants as pre-specified in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Enlicitide Decanoate 20 mg tablet single dose orally on Day 1
Drug: Enlicitide Decanoate
Participants receive Enlicitide Decanoate 20 mg tablet single dose orally on Day 1
Drug: Enlicitide Decanoate
Participants receive Enlicitide Decanoate 20 mg tablet orally on Day 1 and Day 16.
Drug: Enlicitide Decanoate
Participants receive Enlicitide Decanoate 20 mg tablet single dose orally on Day 1.
Drug: Enlicitide Decanoate
Oral dose
Also known as: MK-0616
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate
AUC0-inf was a measure of the total amount of drug in the plasma from the dose administration extrapolated to infinity. Blood for plasma samples was collected at pre-specified timepoints to determine the AUC0-inf of enlicitide decanoate for Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C ESRD - enlicitide decanoate pre-hemodialysis and Panel C ESRD - enlicitide decanoate post-hemodialysis to report AUC0-inf. Per protocol, mean AUC0-inf was reported.
Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
AUC From Time 0 to Last Measurable Concentration (AUClast) of Enlicitide Decanoate
AUClast was defined as the area under the concentration-time curve of enlicitide decanoate from time zero to last measurable concentration. Blood for plasma samples was collected at pre-specified timepoints to determine the AUClast of enlicitide decanoate in Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C ESRD - enlicitide decanoate pre-hemodialysis and Panel C ESRD - enlicitide decanoate post-hemodialysis to report AUClast. Per protocol, mean AUClast was reported.
Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate
Cmax was defined as the maximum or peak concentration of enlicitide decanoate observed after its administration. Blood for plasma samples was collected at pre-specified time points to determine the Cmax of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Cmax. Per protocol, mean Cmax was reported.
Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate
Tmax was defined as the time required for a study drug to reach maximum concentration in plasma. Blood for plasma samples was collected at pre-specified time points to determine the Tmax of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Tmax. Per protocol, mean Tmax was reported.
Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Apparent Terminal Half-life (t1/2) of Enlicitide Decanoate
Half-life (t1/2) was defined as the time required for plasma drug concentration of enclitide decanoate to decrease by 50% from peak. Blood for plasma samples was collected at pre-specified time points to determine the t1/2 of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report t1/2. Per protocol, mean t1/2 was reported.
Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Apparent Clearance (CL/F) of Enlicitide Decanoate
CL/F was the apparent total clearance of enlicitide decanoate in plasma over time. Blood for plasma samples was collected at pre-specified timepoints to determine the CL/F of enlicitide decanoate for Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report CL/F. Per protocol, mean CL/F was reported.
Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Apparent Volume of Distribution (Vz/F) of Enlicitide Decanoate
Vz/F was the apparent volume of distribution of enlicitide decanoate between the plasma and the rest of the body, after dose, assessed as the total volume of enlicitide decanoate that would need to be uniformly distributed to achieve the desired plasma drug concentration. Blood for plasma samples was collected at pre-specified time points to determine the Vz/F of Enlicitide Decanoate in Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Vz/F. Per protocol, mean Vz/F was reported.
Time frame: Predose and 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 120, 168, and 240 hours postdose
Panel C: Dialysate Clearance (CLd) of Enlicitide Decanoate
CLd was the measure of the amount of enlicitide decanoate cleared from plasma via dialysis. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean CLd.
Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Panel C: Dialysate Concentration (Cd) of Enlicitide Decanoate
Cd was the measure of the concentration of enlicitide decanoate in dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean Cd.
Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Panel C: Amount of Enlicitide Decanoate Excreted (AEd) in Dialysate
AEd was the measure of the amount of enlicitide decanoate excreted in the dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean AEd.
Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Panel C: Percentage of Dose (%Dose) of Enlicitide Decanoate Excreted in Dialysate
%Dose was the percentage of the dose of enlicitide decanoate excreted in the dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine %Dose.
Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Amount of Enlicitide Decanoate Excreted in Urine From 0 to 24 Hours (AE0-24) After Administration of Enlicitide Decanoate
AE0-24 was the measure of the amount of enlicitide decanoate excreted at 0 to 24 hours. Urine samples were to be collected to determine the AE0-24 after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report AE0-24. Per protocol, mean AE0-24 was reported.
Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours postdose
Percentage of Unchanged Enlicitide Decanoate Excreted in Urine (Fe)
Fe was the measure of the percentage of unchanged enlicitide decanoate excreted in the urine. The percentage of enlicitide decanoate that was excreted unchanged in urine over the 24-hr collection interval (Fe) was calculated as 100 times the ratio of Ae0-24 and dose. Urine samples were to be collected to determine the Fe after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Fe.
Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Renal Clearance (CLr) of Enlicitide Decanoate
CLr was the measure of how quickly enlicitide decanoate was removed from the plasma by the kidney and excreted in urine. Urine samples were to be collected to determine the CLr after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report CLr. Per protocol, mean CLr was reported.
Time frame: Predose and 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.
Time frame: Up to approximately 30 days
Panels A, B, and D: Number of Participants Who Discontinued From the Study Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of Panel A, B, and D participants who discontinued study treatment due to an AE were reported.
Time frame: Up to approximately 30 days
Panel C: Number of Participants Who Discontinued From the Study Treatment Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of Panel C participants who discontinued study treatment due to an AE were reported.
Time frame: Up to approximately 30 days
| Milestone | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | Panel D: Healthy Controls |
|---|---|---|---|---|
| Started | 8 | 8 | 9 | 8 |
| Completed | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
AUC0-inf was a measure of the total amount of drug in the plasma from the dose administration extrapolated to infinity. Blood for plasma samples was collected at pre-specified timepoints to determine the AUC0-inf of enlicitide decanoate for Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C ESRD - enlicitide decanoate pre-hemodialysis and Panel C ESRD - enlicitide decanoate post-hemodialysis to report AUC0-inf. Per protocol, mean AUC0-inf was reported.
| hr*nmol/Liter | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate | 733 (499 to 1080) | 554 (379 to 809) | 850 (538 to 1350) | 570 (404 to 804) | 487 (316 to 752) |
AUClast was defined as the area under the concentration-time curve of enlicitide decanoate from time zero to last measurable concentration. Blood for plasma samples was collected at pre-specified timepoints to determine the AUClast of enlicitide decanoate in Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C ESRD - enlicitide decanoate pre-hemodialysis and Panel C ESRD - enlicitide decanoate post-hemodialysis to report AUClast. Per protocol, mean AUClast was reported.
| hr*nmol/Liter | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| AUC From Time 0 to Last Measurable Concentration (AUClast) of Enlicitide Decanoate | 735 (506 to 1070) | 362 (145 to 904) | 649 (343 to 1230) | 538 (376 to 769) | 456 (297 to 701) |
Cmax was defined as the maximum or peak concentration of enlicitide decanoate observed after its administration. Blood for plasma samples was collected at pre-specified time points to determine the Cmax of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Cmax. Per protocol, mean Cmax was reported.
| nmol/Liter | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate | 9.56 (6.95 to 13.2) | 5.8 (3.03 to 11.1) | 8.73 (6.23 to 12.2) | 9.08 (6.13 to 13.4) | 9.72 (7.1 to 13.3) |
Tmax was defined as the time required for a study drug to reach maximum concentration in plasma. Blood for plasma samples was collected at pre-specified time points to determine the Tmax of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Tmax. Per protocol, mean Tmax was reported.
| hours | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate | 16 (1 to 24.25) | 2.75 (0.5 to 24) | 18.01 (0.50 to 48) | 1.00 (0.50 to 24) | 1.0 (0.5 to 12.03) |
Half-life (t1/2) was defined as the time required for plasma drug concentration of enclitide decanoate to decrease by 50% from peak. Blood for plasma samples was collected at pre-specified time points to determine the t1/2 of enlicitide decanoate in Panel A, B, C and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report t1/2. Per protocol, mean t1/2 was reported.
| hours | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of Enlicitide Decanoate | 81.5 ± 70.4 | 56.4 ± 32.7 | 53.6 ± 36.9 | 75.6 ± 62.9 | 46 ± 60.8 |
CL/F was the apparent total clearance of enlicitide decanoate in plasma over time. Blood for plasma samples was collected at pre-specified timepoints to determine the CL/F of enlicitide decanoate for Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report CL/F. Per protocol, mean CL/F was reported.
| Liter/hr | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Apparent Clearance (CL/F) of Enlicitide Decanoate | 17.6 (12 to 25.9) | 23.3 (15.9 to 34) | 15.2 (9.58 to 24) | 22.6 (16 to 31.9) | 26.5 (17.2 to 40.8) |
Vz/F was the apparent volume of distribution of enlicitide decanoate between the plasma and the rest of the body, after dose, assessed as the total volume of enlicitide decanoate that would need to be uniformly distributed to achieve the desired plasma drug concentration. Blood for plasma samples was collected at pre-specified time points to determine the Vz/F of Enlicitide Decanoate in Panel A, B, C, and D participants. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Vz/F. Per protocol, mean Vz/F was reported.
| Liter | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Enlicitide Decanoate | 2070 (1370 to 3120) | 1890 (1300 to 2760) | 1170 (845 to 1620) | 2470 (1680 to 3620) | 1760 (1400 to 2210) |
CLd was the measure of the amount of enlicitide decanoate cleared from plasma via dialysis. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean CLd.
No measurements were reported for this outcome.
Cd was the measure of the concentration of enlicitide decanoate in dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean Cd.
No measurements were reported for this outcome.
AEd was the measure of the amount of enlicitide decanoate excreted in the dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine mean AEd.
No measurements were reported for this outcome.
%Dose was the percentage of the dose of enlicitide decanoate excreted in the dialysate. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis. Urine samples were to be collected for Panel C participants to determine %Dose.
No measurements were reported for this outcome.
AE0-24 was the measure of the amount of enlicitide decanoate excreted at 0 to 24 hours. Urine samples were to be collected to determine the AE0-24 after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report AE0-24. Per protocol, mean AE0-24 was reported.
| mg | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Amount of Enlicitide Decanoate Excreted in Urine From 0 to 24 Hours (AE0-24) After Administration of Enlicitide Decanoate | 0.0213 (0.00846 to 0.0538) | 0.00592 (0.00211 to 0.0166) | — | — | 0.0662 (0.0371 to 0.118) |
Fe was the measure of the percentage of unchanged enlicitide decanoate excreted in the urine. The percentage of enlicitide decanoate that was excreted unchanged in urine over the 24-hr collection interval (Fe) was calculated as 100 times the ratio of Ae0-24 and dose. Urine samples were to be collected to determine the Fe after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report Fe.
| Percentage of Enlicitide Decanoate | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Percentage of Unchanged Enlicitide Decanoate Excreted in Urine (Fe) | 0.107 (0.0423 to 0.269) | 0.0296 (0.0105 to 0.0831) | — | — | 0.331 (0.185 to 0.591) |
CLr was the measure of how quickly enlicitide decanoate was removed from the plasma by the kidney and excreted in urine. Urine samples were to be collected to determine the CLr after administration of enlicitide decanoate for Panels A, B, C, and D. Per protocol, Panel C ESRD on HD arm was separated into two arms: Panel C enlicitide decanoate pre-hemodialysis and Panel C enlicitide decanoate post-hemodialysis to report CLr. Per protocol, mean CLr was reported.
| Liter/hr | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: ESRD - Enlicitide Decanoate Pre-Hemodialysis | Panel C: ESRD - Enlicitide Decanoate Post-Hemodialysis | Panel D: Healthy Controls |
|---|---|---|---|---|---|
| Renal Clearance (CLr) of Enlicitide Decanoate | 0.0716 (0.0349 to 0.147) | 0.0347 (0.0114 to 0.106) | — | — | 0.243 (0.161 to 0.366) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.
| Participants | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | Panel D: Healthy Controls |
|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 2 | 2 | 1 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of Panel A, B, and D participants who discontinued study treatment due to an AE were reported.
| Participants | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel D: Healthy Controls |
|---|---|---|---|
| Panels A, B, and D: Number of Participants Who Discontinued From the Study Due to an AE | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of Panel C participants who discontinued study treatment due to an AE were reported.
| Participants | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) |
|---|---|
| Panel C: Number of Participants Who Discontinued From the Study Treatment Due to an AE | 0 |
Collected over Up to approximately 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A: Moderate Renal Impairment (RI) | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Panel B: Severe RI | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | 0/9 (0%) | 1/9 (11.1%) | 0/9 (0%) |
| Panel D: Healthy Controls | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | Panel D: Healthy Controls |
|---|---|---|---|---|
| HypervolaemiaMetabolism and nutrition disorders | 0/8 | 0/8 | 1/9 | 0/8 |
| Event | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | Panel D: Healthy Controls |
|---|---|---|---|---|
| Dry mouthGastrointestinal disorders | 1/8 | 0/8 | 0/9 | 0/8 |
| Animal biteInjury, poisoning and procedural complications | 0/8 | 1/8 | 0/9 | 0/8 |
| HypertensionVascular disorders | 1/8 | 0/8 | 0/9 | 0/8 |
| Orthostatic hypotensionVascular disorders | 0/8 | 1/8 | 0/9 | 0/8 |
All allocated participants
| Age, Continuous(Years) | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | Panel D: Healthy Controls | Total |
|---|---|---|---|---|---|
| Mean | 67 ± 9.6 | 66.8 ± 12.1 | 60.1 ± 9.6 | 62.8 ± 4 | 64 ± 9.3 |
| Sex: Female, Male(Participants) | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | Panel D: Healthy Controls | Total |
|---|---|---|---|---|---|
| Female | 1 | 5 | 1 | 2 | 9 |
| Male | 7 | 3 | 8 | 6 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | Panel D: Healthy Controls | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 2 | 5 | 15 |
| Not Hispanic or Latino | 2 | 6 | 7 | 3 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Panel A: Moderate Renal Impairment (RI) | Panel B: Severe RI | Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD) | Panel D: Healthy Controls | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 5 | 7 | 3 | 16 |
| White | 7 | 3 | 2 | 5 | 17 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jul 2023 to primary completion in Jan 2024, 5 months.
Results were first posted in Feb 2025, 1 year after primary completion.
Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 5 months is below that.
Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-0616